Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Palbociclib + Letrozole in HR+/HER2- Breast Cancer (DxCARTES)
NCT03819010Phase 2Completed
- Sponsor
- MEDSIR
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of palbociclib in breast cancer (2 cohorts), sponsored by MEDSIR. Primary endpoint: Difference on Recurrence Score between pre and post-treatment at 6 months. Started May 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03819010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819010.